Sodium ascorbate

Explore a selection of our essential drug information below, or:

CREATE FREE ACCOUNT

Full Drug Profiles

Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.

SUBSCRIBERECOMMENDED FOR PHARMA

Data Packages

Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.

Identification

Brand Names

Irospan 24/6 Kit, Mega-C, Moviprep, Plenvu, Tandem Plus

Generic Name

Sodium ascorbate

DrugBank Accession Number

DB14482

Background

Not Available

Type

Small Molecule

Groups

Approved, Nutraceutical

Structure

Download

MOLSDFPDBSMILESInChI

Similar Structures

Structure for Sodium ascorbate (DB14482)

×

Close

Weight

Average: 198.106
Monoisotopic: 198.01403223

Chemical Formula

C₆H₇NaO₆

Synonyms

• Ascorbato sódico
• Ascorbic acid sodium salt
• L-Ascorbic acid sodium salt
• L-Ascorbic acid, monosodium salt
• Monosodium L-ascorbate
• Sodium ascorbate
• sodium L-ascorbate
• Vitamin C sodium
• Vitamin C, sodium salt

Unlock the secrets to drugging the undruggable

Discover how groundbreaking research is turning "undruggable" targets into therapeutic opportunities.

Download eBook

Unlock the secrets to drugging the undruggable

Download eBook

Pharmacology

Indication

Not Available

Reduce drug development failure rates

Build, train, & validate machine-learning models
with evidence-based and structured datasets.

See how

Build, train, & validate predictive machine-learning models with structured datasets.

See how

Associated Conditions

Indication Type	Indication	Combined Product Details	Approval Level	Age Group	Patient Characteristics	Dose Form
Used in combination for symptomatic treatment of	Common cold	Combination Product in combination with: Acetaminophen (DB00316)	••••••••••••			••••••• ••••••• ••••••••••••
Used in combination for symptomatic treatment of	Coughing	Combination Product in combination with: Menglytate (DB15983)	••• •••			••••••• •••••• ••••••••••••••
Used in combination for symptomatic treatment of	Fever	Combination Product in combination with: Acetaminophen (DB00316)	••••••••••••			••••••• ••••••• ••••••••••••
Used in combination for symptomatic treatment of	Fever	Combination Product in combination with: Acetaminophen (DB00316)	••• •••			••••••• ••••••• ••••••••••••
Used in combination for symptomatic treatment of	Flu caused by influenza	Combination Product in combination with: Acetaminophen (DB00316)	••••••••••••			••••••• ••••••• ••••••••••••

Create Account

Associated Therapies

• Airway secretion clearance therapy
• Nutritional supplementation
• Vitamin supplementation

Contraindications & Blackbox Warnings

Prevent Adverse Drug Events Today

Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.

Learn more

Avoid life-threatening adverse drug events with our Clinical API

Learn more

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Improve decision support & research outcomes

With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!

See the data

Improve decision support & research outcomes with our structured adverse effects data.

See a data sample

Toxicity

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Integrate drug-drug interactions in your software
Acetazolamide	The risk or severity of dehydration can be increased when Acetazolamide is combined with Sodium ascorbate.
Aclidinium	The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Aclidinium.
Alfentanil	The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Alfentanil.
Alloin	The risk or severity of adverse effects can be increased when Sodium ascorbate is combined with Alloin.
Amantadine	The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Amantadine.

Food Interactions

No interactions found.

Products

Drug product information from 10+ global regions

Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.

Access now

Access drug product information from over 10 global regions.

Access now

Active Moieties

Name	Kind	UNII	CAS	InChI Key
Ascorbic acid	unknown	PQ6CK8PD0R	50-81-7	CIWBSHSKHKDKBQ-JLAZNSOCSA-N
Sodium cation	ionic	LYR4M0NH37	17341-25-2	FKNQFGJONOIPTF-UHFFFAOYSA-N

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Mega-C-sodium Inj 250mg/ml	Solution	250 mg / mL	Intravenous	Kripps Pharmacy Ltd.	1981-12-31	Not applicable
Vitamin C	Liquid	250 mg / mL	Intramuscular; Intravenous	Sandoz S.P.A.	1989-12-31	Not applicable

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
C Wafer 500 Chewable 500mg	Wafer	500 mg / waf	Oral	Nu Life Nutrition Ltd.	1986-12-31	2000-05-23
Natural Fruit Chew C 250mg Tangy Orange Flavour	Tablet	250 mg	Oral	Natural Factors Nutritional Products Ltd.	2001-01-01	2009-09-28
Sodium Ascor Crystal 888.8mg/gm USP	Powder	888.8 mg / g	Oral	Vita Health Products Inc	1996-10-11	2002-07-31
Tgi Tab 50mg	Tablet	50 mg / tab	Oral	Seroyal International Inc.	1980-12-31	1996-09-10
Vitamin C 60mg	Tablet	60 mg	Oral	Wn Pharmaceuticals Ltd.	1999-04-09	2008-07-17

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Animal Shaped Chew Vit C Tab 250mg	Sodium ascorbate (159 mg) + Ascorbic acid (110 mg)	Tablet	Oral	Hall Laboratories, Ltd.	1982-12-31	2003-09-11
Appedrine	Sodium ascorbate (10 mg) + Benzocaine (3 mg) + Ferrous fumarate (3.33 mg) + Nicotinamide (3.33 mg) + Riboflavin (.4 mg) + Thiamine hydrochloride (.33 mg) + Vitamin A acetate (1333 unit) + Vitamin D (133 unit)	Tablet	Oral	Chattem, Inc.	1975-12-31	2004-07-08
Ascorbex 500 Tab	Sodium ascorbate (337.5 mg) + Ascorbic acid (200 mg)	Tablet	Oral	SantÉ Naturelle (Ag) LtÉe	1988-12-31	2004-08-05
BENAGOL	Sodium ascorbate (74.9 mg) + Amylmetacresol (0.6 mg) + Ascorbic acid (33.5 mg) + Dichlorobenzyl alcohol (1.2 mg)	Tablet	Transmucosal	Reckitt Benckiser Healthcare (Italia) S.P.A.	2014-07-08	Not applicable
BENAGOL	Sodium ascorbate (74.9 mg) + Amylmetacresol (0.6 mg) + Ascorbic acid (33.5 mg) + Dichlorobenzyl alcohol (1.2 mg)	Tablet	Transmucosal	Reckitt Benckiser Healthcare (Italia) S.P.A.	2014-07-08	Not applicable

Unapproved/Other Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End	Region	Image
Centratex	Sodium ascorbate (200 mg/1) + Cupric sulfate (0.8 mg/1) + Cyanocobalamin (15 ug/1) + Folic acid (1 mg/1) + Iron (106 mg/1) + Magnesium sulfate (6.9 mg/1) + Manganese sulfate (1.3 mg/1) + Nicotinamide (30 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (5 mg/1) + Riboflavin (6 mg/1) + Thiamine mononitrate (10 mg/1) + Zinc sulfate, unspecified form (18.2 mg/1)	Capsule	Oral	Centurion Labs	2009-06-14	Not applicable
Davimet	Sodium ascorbate (36 mg/1) + Ascorbic acid (24 mg/1) + Cholecalciferol (10 ug/1) + Cyanocobalamin (4.5 ug/1) + DL-alpha tocopheryl acetate (10 mg/1) + Folic acid (1667 ug/1) + Niacin (13.5 mg/1) + Pyridoxine hydrochloride (1.05 mg/1) + Riboflavin (1.2 mg/1) + Thiamine mononitrate (1.05 mg/1) + Vitamin A (750 ug/1)	Tablet, chewable	Oral	PureTek Corporation	2022-09-19	Not applicable
Davimet with Fluoride	Sodium ascorbate (36 mg/1) + Ascorbic acid (24 mg/1) + Cholecalciferol (10 ug/1) + DL-alpha tocopheryl acetate (6.75 mg/1) + Levomefolate calcium (1000 ug/1) + Mecobalamin (4.5 ug/1) + Niacin (13.5 mg/1) + Pyridoxine hydrochloride (1.05 mg/1) + Riboflavin (1.2 mg/1) + Sodium fluoride (0.75 mg/1) + Thiamine mononitrate (1.05 mg/1) + Vitamin A (750 ug/1)	Tablet, chewable	Oral	PureTek Corporation	2024-02-28	Not applicable
Davimet with Iron	Sodium ascorbate (36 mg/1) + Ascorbic acid (24 mg/1) + Cholecalciferol (10 ug/1) + DL-alpha tocopheryl acetate (6.75 mg/1) + Iron (11 mg/1) + Levomefolate calcium (1000 ug/1) + Mecobalamin (4.5 ug/1) + Nicotinamide (13.5 mg/1) + Pyridoxine hydrochloride (1.05 mg/1) + Riboflavin (1.2 mg/1) + Thiamine mononitrate (1.05 mg/1) + Vitamin A acetate (750 ug/1)	Tablet	Oral	PureTek Corporation	2024-06-03	Not applicable
Davimet-M	Sodium ascorbate (36 mg/1) + Ascorbic acid (24 mg/1) + Cholecalciferol (10 ug/1) + DL-alpha tocopheryl acetate (10 mg/1) + Levomefolate calcium (1000 ug/1) + Mecobalamin (4.5 ug/1) + Niacin (13.5 mg/1) + Pyridoxine hydrochloride (1.05 mg/1) + Riboflavin (1.2 mg/1) + Thiamine mononitrate (1.05 mg/1) + Vitamin A (750 ug/1)	Tablet, chewable	Oral	PureTek Corporation	2023-11-30	Not applicable

Categories

Drug Categories

• Acids, Acyclic
• Antioxidants
• Biological Factors
• Carbohydrates
• Compounds used in a research, industrial, or household setting
• Diet, Food, and Nutrition
• Food
• Hydroxy Acids
• Laxatives
• Micronutrients
• Physiological Phenomena
• Protective Agents
• Sugar Acids
• Urinary Acidifying Agents
• Vitamin C and analogues
• Vitamins

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as butenolides. These are dihydrofurans with a carbonyl group at the C2 carbon atom.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Dihydrofurans

Sub Class

Furanones

Direct Parent

Butenolides

Alternative Parents

Vinylogous acids / Enoate esters / Secondary alcohols / Lactones / 1,2-diols / Oxacyclic compounds / Monocarboxylic acids and derivatives / Primary alcohols / Organic zwitterions / Organic sodium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds

show 3 more

Substituents

1,2-diol / 2-furanone / Alcohol / Aliphatic heteromonocyclic compound / Alpha,beta-unsaturated carboxylic ester / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Enoate ester / Hydrocarbon derivative / Lactone / Monocarboxylic acid or derivatives / Organic alkali metal salt / Organic oxide / Organic oxygen compound / Organic salt / Organic sodium salt / Organic zwitterion / Organooxygen compound / Oxacycle / Primary alcohol / Secondary alcohol / Vinylogous acid

show 13 more

Molecular Framework

Aliphatic heteromonocyclic compounds

External Descriptors

Not Available

Affected organisms

Not Available

Chemical Identifiers

UNII

S033EH8359

CAS number

134-03-2

InChI Key

PPASLZSBLFJQEF-RXSVEWSESA-M

InChI

InChI=1S/C6H8O6.Na/c7-1-2(8)5-3(9)4(10)6(11)12-5;/h2,5,7-10H,1H2;/q;+1/p-1/t2-,5+;/m0./s1

IUPAC Name

sodium (2R)-2-[(1S)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2,5-dihydrofuran-3-olate

SMILES

[Na+].[H][C@@]1(OC(=O)C(O)=C1[O-])[C@@H](O)CO

References

General References

Not Available

External Links

KEGG Drug

D05853

ChemSpider

16736174

ChEBI

113451

ChEMBL

CHEMBL591665

PharmGKB

PA166163262

Wikipedia

Sodium_ascorbate

Clinical Trials

Clinical Trials

Clinical Trial & Rare Diseases Add-on Data Package

Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package

Phase	Status	Purpose	Conditions	Count	Start Date	Why Stopped	100+ additional columns
Unlock 175K+ rows when you subscribe.View sample data
Not Available	Completed	Not Available	Colon Adenomas / Colon Cancer / Colon Cancer, Rectal Cancer / Colon Polyps	1	somestatus	stop reason	just information to hide
Not Available	Completed	Not Available	Colon Cancer / Colon Cleansing / Colonic Diseases	1	somestatus	stop reason	just information to hide
Not Available	Completed	Not Available	Hyponatremia	1	somestatus	stop reason	just information to hide
Not Available	Completed	Supportive Care	Colorectal Adenomas / Colorectal Cancer	1	somestatus	stop reason	just information to hide
Not Available	Terminated	Diagnostic	Colonoscopy	1	somestatus	stop reason	just information to hide

Unlock 75,000+ rows when you subscribe

Explore data packages curated & structured to speed up your pharmaceutical research

View Sample Data

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Solution	Intravenous	10 g
Tablet	Transmucosal
Wafer	Oral	500 mg / waf
Tablet	Oral
Tablet, orally disintegrating	Transmucosal
Capsule	Cutaneous; Oral
Capsule, delayed release	Oral
Kit; tablet; tablet, film coated	Oral
Capsule, liquid filled	Oral	560 mg
Solution	Intravenous	250 mg / mL
Kit	Oral
Kit; solution	Oral
Powder, for solution	Oral
Solution	Oral
Tablet, chewable	Oral
Tablet, film coated
Tablet	Oral	250 mg
Capsule, gelatin coated; kit; tablet	Oral
Tablet, film coated	Oral
Kit	Intravenous
Capsule, liquid filled	Oral
Kit; powder, for solution	Oral
Powder, for solution	Oral	7.54 g
Liquid	Oral
Powder	Oral
Capsule, gelatin coated	Oral
Tablet, effervescent	Oral
Powder	Oral	888.8 mg / g
Injection, solution	Intravenous
Injection, powder, for solution	Intravenous
Injection, powder, lyophilized, for solution	Intravenous
Powder, for solution	Intravenous
Capsule	Oral
Tablet	Oral	50 mg / tab
Tablet, coated	Oral
Liquid	Intramuscular; Intravenous	250 mg / mL
Tablet	Oral	60 mg
Tablet, chewable	Buccal
Lozenge	Oral

Prices

Not Available

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)	Region
US7169381	No	2007-01-30	2024-09-01
US7658914	No	2010-02-09	2024-09-01
US9326969	No	2016-05-03	2033-09-10
US9592252	No	2017-03-14	2032-08-11
US9707297	No	2017-07-18	2033-09-10
US8999313	No	2015-04-07	2033-09-10
US10016504	No	2018-07-10	2033-09-10
US10646512	No	2020-05-12	2032-03-25
US10792306	No	2020-10-06	2032-03-09
US10780112	No	2020-09-22	2032-03-09
US10918723	No	2021-02-16	2033-09-10
US11529368	No	2012-03-09	2032-03-09

Properties

State

Not Available

Experimental Properties

Not Available

Predicted Properties

Property	Value	Source
Water Solubility	625.0 mg/mL	ALOGPS
logP	-1.4	ALOGPS
logP	-1.9	Chemaxon
logS	0.5	ALOGPS
pKa (Strongest Acidic)	4.36	Chemaxon
pKa (Strongest Basic)	-3	Chemaxon
Physiological Charge	-1	Chemaxon
Hydrogen Acceptor Count	5	Chemaxon
Hydrogen Donor Count	3	Chemaxon
Polar Surface Area	110.05 Å2	Chemaxon
Rotatable Bond Count	2	Chemaxon
Refractivity	47.58 m3·mol-1	Chemaxon
Polarizability	14.51 Å3	Chemaxon
Number of Rings	1	Chemaxon
Bioavailability	1	Chemaxon
Rule of Five	Yes	Chemaxon
Ghose Filter	No	Chemaxon
Veber's Rule	No	Chemaxon
MDDR-like Rule	No	Chemaxon

Predicted ADMET Features

Not Available

Spectra

Mass Spec (NIST)

Not Available

Spectra

Not Available

Chromatographic Properties

Collision Cross Sections (CCS)

Adduct	CCS Value (Å2)	Source type	Source
[M-H]-	136.8172793	predicted	DarkChem Lite v0.1.0
[M-H]-	136.0677793	predicted	DarkChem Lite v0.1.0
[M-H]-	136.15067	predicted	DeepCCS 1.0 (2019)
[M+H]+	136.7731793	predicted	DarkChem Lite v0.1.0
[M+H]+	136.5461793	predicted	DarkChem Lite v0.1.0
[M+H]+	138.3495	predicted	DeepCCS 1.0 (2019)
[M+Na]+	136.2521793	predicted	DarkChem Lite v0.1.0
[M+Na]+	136.7061793	predicted	DarkChem Lite v0.1.0
[M+Na]+	144.26205	predicted	DeepCCS 1.0 (2019)

×

Identify potential medication risks

Easily compare up to 40 drugs with our drug interaction checker.

Get severity rating, description, and management advice.

Learn more

Drug created at July 06, 2018 22:02 / Updated at October 10, 2024 12:49